News and Trends 7 Dec 2022 ExPLoRNA Therapeutics receives mRNA technology funding ExPLoRNA Therapeutics, a Polish biotech company working on mRNA vaccines and therapeutics, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. ExPLoRNA specializes in novel cap analogs, the starting part of mRNA crucial for enabling successful production of the encoded protein. ExPLoRNA’s technology increases protein production beyond the […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Pixelgen Technologies emerges to advance single-cell spatial proteomics Pixelgen Technologies has emerged from stealth with a mission to bring a new dimension to single-cell spatial proteomics. The launch follows the close of an approximate $6 million seed round, led by Navigare Ventures, which will support the commercialization next year of the company’s molecular pixelation technology for spatial analyses of cell surface proteins in […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders Apogee Therapeutics, LLC, a biotech company advancing novel, potentially best-in-class therapies to address immunological and inflammatory disorders, has announced the closing of a $149 million Series B financing. Proceeds will be used to support Apogee’s plans to advance its lead pipeline program into the clinic in 2023 and expand the leadership, scientific, and clinical teams […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 PacBio and Boston Children’s Hospital to study genome to benefit patients PacBio, a developer of sequencing solutions, says its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital in the U.S. Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with […] December 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Step Pharma and Concr to partner on cancer treatment Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, and Concr, a techbio company with a statistical learning-powered biomarker prediction engine, have entered a partnership to identify biomarkers to improve therapeutic response to inhibitors of cytidine triphosphate synthase 1 (CTPS1), an enzyme to which all cancers appear to be addicted. Concr’s […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 BiVictriX identifies development lead for ADC cancer program BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has identified a development lead for its BVX001 program. The lead was developed using BiVictriX’s proprietary Bi-Cygni approach, which aims to generate the next-generation of antibody drug conjugates (ADCs) with superior […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Scientists identify genetic variant causing ALS in some patients Researchers at Nagoya University in Japan have identified a novel genetic variant found in some patients with amyotrophic lateral sclerosis (ALS). Employing human-induced pluripotent stem (iPS) cells, they detailed the process by which this variant relates to ALS. The investigators say they expect this mechanism to be a new therapeutic target for ALS treatment. The […] December 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Rani Therapeutics reveals results from phase 1 osteoporosis study Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of […] December 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 FDA clears insulin pen medical device BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Tetra announce significant results from the study of Onternabez combined with Favipiravir Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […] December 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email